ticlopidine has been researched along with Hyperplasia in 27 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The PRODIGY trial aims to assess whether 24 months of clopidogrel therapy improves cardiovascular outcomes after coronary intervention in a broad all-comer patient population receiving a balanced mixture of stents with various anti-intimal hyperplasia potency." | 9.14 | Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment ( Arcozzi, C; Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Colombo, F; Ferrari, F; Ferrari, R; Frangione, A; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Zuffi, A, 2010) |
| " The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound." | 9.14 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS)." | 9.12 | Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. ( Choi, D; Jang, Y; Jung, JH; Ko, YG; Min, PK; Shim, WH, 2007) |
| "Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents." | 9.10 | A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003) |
| "Compared to clopidogrel and prasugrel, ticagrelor reduced neointimal formation, endothelial dysfunction, and peri-strut inflammation." | 7.85 | Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. ( Chang, KS; Hong, YJ; Jeong, MH; Kim, HK; Kim, JH; Kim, MC; Kim, SS; Lim, HC; Lim, KS; Park, KH, 2017) |
| "The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess device-specific outcomes relative to different duration of dual antiplatelet therapy (DAPT) after Everolimus- (EES), Paclitaxel (PES), Zotarolimus- (ZES-S) eluting, or bare metal stents (BMS)." | 5.17 | Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). ( Borghesi, M; Ferrari, R; Parrinello, G; Tebaldi, M; Valgimigli, M; Vranckx, P, 2013) |
| "The PRODIGY trial aims to assess whether 24 months of clopidogrel therapy improves cardiovascular outcomes after coronary intervention in a broad all-comer patient population receiving a balanced mixture of stents with various anti-intimal hyperplasia potency." | 5.14 | Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment ( Arcozzi, C; Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Colombo, F; Ferrari, F; Ferrari, R; Frangione, A; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Zuffi, A, 2010) |
| " The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound." | 5.14 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS)." | 5.12 | Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. ( Choi, D; Jang, Y; Jung, JH; Ko, YG; Min, PK; Shim, WH, 2007) |
| "Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents." | 5.10 | A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003) |
| "Compared to clopidogrel and prasugrel, ticagrelor reduced neointimal formation, endothelial dysfunction, and peri-strut inflammation." | 3.85 | Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. ( Chang, KS; Hong, YJ; Jeong, MH; Kim, HK; Kim, JH; Kim, MC; Kim, SS; Lim, HC; Lim, KS; Park, KH, 2017) |
| "Ninety-minute ischemia before vein grafting can cause serious EC loss, but does not increase early intimal hyperplasia when clopidogrel is administered." | 3.78 | Influence of ischemia before vein grafting on early hyperplasia of the graft and the dynamic changes of the intima after grafting. ( Guo, Q; Lu, Z; Sun, M; Zou, R, 2012) |
| "The purpose of this study was to compare the effects of ticlopidine and clopidogrel on the development of neointimal hyperplasia after experimental arterial injury." | 3.76 | Inhibitory effects of ticlopidine and clopidogrel on the intimal hyperplastic response after arterial injury. ( Ari, H; Bayer, A; Göncü, T; Ozcan, A; Ozyazicioğlu, A; Sezen, M; Tiryakioğlu, O; Vural, H; Yalçinkaya, S; Yavuz, S, 2010) |
| "Reducing the dose of sirolimus eluting from a biocompatible HAp coated stent reduces signs of delayed vascular healing, without affecting neointimal hyperplasia." | 3.75 | Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing. ( Peters-Krabbendam, I; Serruys, PW; Sorop, O; van Beusekom, HM; van der Giessen, WJ, 2009) |
| "The efficacy of a postoperative treatment with Low molecular weight heparin (LMWH) vs Ticlopidine in controlling early thrombosis, intimal hyperplasia and growth of true endothelial cells in small prosthetic expanded polytetrafluoroethylene (ePTFE) grafts (4 mm) interposed in the carotid artery of sheep has been evaluated." | 3.69 | Pharmacological control of intimal hyperplasia in small diameter polytetrafluoroethylene grafts. An experimental study. ( Baccini, P; Bachi, V; Ceppa, P; Civalleri, D; Decian, F; Desalvo, P; Galleano, R; Lenti, E; Simoni, G, 1996) |
| "Intimal hyperplasia is a major cause of restenosis after the interventional or surgical treatment of occlusive arterial disease." | 1.35 | Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass. ( Bahcivan, M; Erenler, BH; Gol, MK; Keceligil, HT; Kolbakir, F; Yucel, S, 2009) |
| "Intimal hyperplasia is one of the main risk factors for the patency of small diameter bypass grafts." | 1.29 | [Prevention of vascular intimal hyperplasia in small caliber prostheses. Preliminary results]. ( Baccini, P; Baiardi, A; Cariati, P; Ceppa, P; Civalleri, D; Desalvo, P; Galleano, R; Lenti, E; Simoni, G, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 14 (51.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, HK | 1 |
| Jeong, MH | 1 |
| Lim, KS | 1 |
| Kim, JH | 2 |
| Lim, HC | 1 |
| Kim, MC | 1 |
| Hong, YJ | 1 |
| Kim, SS | 1 |
| Park, KH | 1 |
| Chang, KS | 1 |
| Nikuhinikov, PI | 1 |
| Bytsay, AN | 1 |
| Lysak, LI | 1 |
| Yatsenko, AI | 1 |
| Abramenko, AV | 1 |
| Jerzewski, K | 1 |
| Ruel, M | 3 |
| Voisine, P | 3 |
| Le May, MR | 2 |
| Kulik, A | 3 |
| Une, D | 1 |
| Le May, M | 1 |
| Valgimigli, M | 5 |
| Tebaldi, M | 3 |
| Borghesi, M | 3 |
| Vranckx, P | 4 |
| Campo, G | 3 |
| Tumscitz, C | 2 |
| Cangiano, E | 2 |
| Minarelli, M | 2 |
| Scalone, A | 2 |
| Cavazza, C | 2 |
| Marchesini, J | 2 |
| Parrinello, G | 3 |
| Costa, F | 2 |
| Leonardi, S | 2 |
| Moscarella, E | 1 |
| Ando, G | 1 |
| Calabro, P | 1 |
| Oreto, G | 1 |
| Zijlstra, F | 1 |
| Gargiulo, G | 1 |
| Ariotti, S | 1 |
| Biscaglia, S | 1 |
| Esposito, G | 1 |
| Windecker, S | 1 |
| Hemetsberger, R | 1 |
| Farhan, S | 1 |
| Strehblow, C | 1 |
| Sperker, W | 1 |
| Pavo, I | 1 |
| Petrasi, Z | 1 |
| Hemetsberger, H | 1 |
| Posa, A | 1 |
| Huber, K | 1 |
| Glogar, D | 1 |
| Gyöngyösi, M | 1 |
| van der Giessen, WJ | 2 |
| Sorop, O | 1 |
| Serruys, PW | 2 |
| Peters-Krabbendam, I | 1 |
| van Beusekom, HM | 1 |
| Yucel, S | 1 |
| Bahcivan, M | 1 |
| Gol, MK | 1 |
| Erenler, BH | 1 |
| Kolbakir, F | 1 |
| Keceligil, HT | 1 |
| Göncü, T | 1 |
| Tiryakioğlu, O | 1 |
| Ozcan, A | 1 |
| Ari, H | 1 |
| Sezen, M | 1 |
| Vural, H | 1 |
| Bayer, A | 1 |
| Yalçinkaya, S | 1 |
| Yavuz, S | 1 |
| Ozyazicioğlu, A | 1 |
| Percoco, G | 1 |
| Monti, M | 1 |
| Ferrari, F | 1 |
| Zuffi, A | 1 |
| Colombo, F | 1 |
| Kubbajeh, M | 1 |
| Arcozzi, C | 1 |
| Frangione, A | 1 |
| Ferrari, R | 2 |
| Tardif, JC | 1 |
| Delarochelliere, R | 1 |
| Naidoo, S | 1 |
| Wells, GA | 1 |
| Mesana, TG | 1 |
| Gasparovic, H | 1 |
| Petricevic, M | 1 |
| Biocina, B | 1 |
| Bisdas, T | 1 |
| Haverich, A | 1 |
| Teebken, OE | 1 |
| Zou, R | 1 |
| Sun, M | 1 |
| Lu, Z | 1 |
| Guo, Q | 1 |
| Park, SJ | 2 |
| Shim, WH | 2 |
| Ho, DS | 1 |
| Raizner, AE | 1 |
| Park, SW | 2 |
| Hong, MK | 2 |
| Lee, CW | 2 |
| Choi, D | 2 |
| Jang, Y | 2 |
| Lam, R | 1 |
| Weissman, NJ | 1 |
| Mintz, GS | 1 |
| Wijns, W | 1 |
| Sianos, G | 1 |
| de Scheerder, I | 1 |
| van den Heuvel, PA | 1 |
| Rutsch, W | 1 |
| Glogar, HD | 1 |
| Macaya, C | 1 |
| Materne, PH | 1 |
| Veldhof, S | 1 |
| Vonhausen, H | 1 |
| Otto-Terlouw, PC | 1 |
| Melero, JM | 1 |
| Porras, C | 1 |
| Such, M | 1 |
| Olalla, E | 1 |
| Alonso, J | 1 |
| Mukherjee, D | 1 |
| Finn, AV | 1 |
| Joner, M | 1 |
| Nakazawa, G | 1 |
| Kolodgie, F | 1 |
| Newell, J | 1 |
| John, MC | 1 |
| Gold, HK | 1 |
| Virmani, R | 1 |
| Min, PK | 1 |
| Jung, JH | 1 |
| Ko, YG | 1 |
| Lee, SW | 1 |
| Kim, YH | 1 |
| Yun, SC | 1 |
| Park, DW | 1 |
| Kim, HS | 1 |
| Ko, JK | 1 |
| Park, JH | 1 |
| Lee, JH | 1 |
| Choi, SW | 1 |
| Seong, IW | 1 |
| Cho, YH | 1 |
| Lee, NH | 1 |
| Chun, KJ | 1 |
| Simoni, G | 2 |
| Galleano, R | 2 |
| Ceppa, P | 2 |
| Desalvo, P | 2 |
| Cariati, P | 1 |
| Baccini, P | 2 |
| Lenti, E | 2 |
| Baiardi, A | 1 |
| Civalleri, D | 2 |
| Decian, F | 1 |
| Bachi, V | 1 |
| Marx, SO | 1 |
| Marks, AR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Short-term Outcomes of Elective High-risk PCI With Extracorporeal Membrane Oxygenation Support: a Single-centre Registry[NCT05387902] | 25 participants (Actual) | Observational [Patient Registry] | 2022-02-03 | Completed | |||
| A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
| In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030] | Phase 4 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
| The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204] | 60 participants (Actual) | Interventional | 2008-05-31 | Completed | |||
| Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894] | 0 participants (Actual) | Observational | 2010-11-30 | Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.) | |||
| Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837] | 33 participants (Actual) | Observational | 2014-12-31 | Completed | |||
| Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949] | 8 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Cardiac Allograft Remodeling and Effects of Sirolimus on Its Progression[NCT01889992] | Phase 1 | 42 participants (Actual) | Interventional | 2013-04-24 | Terminated (stopped due to PI left University and project not continued) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 85% up to 90% stent coverage | 90% up to 95% stent coverage | 95% or greater percent stent coverage | |
| NIDDM Patients Receiving the Resolute Stent | 0 | 1 | 0 |
| Non-diabetic Patients Receiving the Resolute Stent | 1 | 3 | 1 |
1 review available for ticlopidine and Hyperplasia
| Article | Year |
|---|---|
Percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Diabetic Angiopathies; Humans; | 2005 |
12 trials available for ticlopidine and Hyperplasia
14 other studies available for ticlopidine and Hyperplasia
| Article | Year |
|---|---|
Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model.
Topics: Adenosine; Animals; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Endothelium, Vascular; Hy | 2017 |
[[Impact of plestazol preparation on hyperplasia of inter vascular layer in the patients, suffering obliterating atherosclerosis of the lower extremities arteries after reconstructive operations].]
Topics: Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Biomarkers; Case-Control Studies; Cilostazol; | 2016 |
Association between the efficacy of dual antiplatelet therapy and the development of in-stent neointimal hyperplasia in porcine coronary arteries.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Animals; Aspirin; Cell Proliferation; Clopido | 2008 |
Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materia | 2009 |
Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass.
Topics: Administration, Oral; Animals; Atorvastatin; Benzopyrans; Calcium Dobesilate; Cardiovascular Agents; | 2009 |
Inhibitory effects of ticlopidine and clopidogrel on the intimal hyperplastic response after arterial injury.
Topics: Angioplasty, Balloon; Animals; Clopidogrel; Fibroblast Growth Factors; Hyperplasia; Iliac Artery; Pl | 2010 |
Letter by Gasparovic et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Dr | 2011 |
Letter by Bisdas et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary | 2011 |
Influence of ischemia before vein grafting on early hyperplasia of the graft and the dynamic changes of the intima after grafting.
Topics: Animals; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cell Proliferation; Clopidog | 2012 |
Severe stenosis of anastomoses by using the symmetry aortic connector system.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Arter | 2004 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
[Prevention of vascular intimal hyperplasia in small caliber prostheses. Preliminary results].
Topics: Animals; Anticoagulants; Blood Vessel Prosthesis; Disease Models, Animal; Drug Evaluation, Preclinic | 1995 |
Pharmacological control of intimal hyperplasia in small diameter polytetrafluoroethylene grafts. An experimental study.
Topics: Animals; Blood Vessel Prosthesis; Carotid Arteries; Carotid Artery Thrombosis; Endothelium, Vascular | 1996 |
Bench to bedside: the development of rapamycin and its application to stent restenosis.
Topics: Angioplasty, Balloon, Coronary; Animals; Calcineurin Inhibitors; Carrier Proteins; Cell Cycle Protei | 2001 |